Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950142-24-000711
Filing Date
2024-03-15
Accepted
2024-03-15 10:08:36
Documents
2
Group Members
GAP (BERMUDA) L.P.GAP COINVESTMENTS CDA, L.P.GAP COINVESTMENTS III, LLCGAP COINVESTMENTS IV, LLCGAP COINVESTMENTS V, LLCGENERAL ATLANTIC (AK), L.P.GENERAL ATLANTIC (LUX) S.A.R.L.GENERAL ATLANTIC (SPV) GP, LLCGENERAL ATLANTIC GENPAR (BERMUDA), L.P.GENERAL

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G eh240458442_13g-akro.htm SC 13G 242518
2 EXHIBIT 99.1 eh240458442_ex01.htm EX-99.1 36042
  Complete submission text file 0000950142-24-000711.txt   281100
Mailing Address 55 EAST 52ND STREET 33RD FLOOR NEW YORK NY 10055
Business Address 55 EAST 52ND STREET 33RD FLOOR NEW YORK NY 10055 212 715 4000
GENERAL ATLANTIC, L.P. (Filed by) CIK: 0001017645 (see all company filings)

EIN.: 133503735 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Subject) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91047 | Film No.: 24752897
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)